Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05035017 · ClinicalTrials.gov registry record
Clinical Validation of the Apollo Daily Disposable Soft Contact Lenses
A clinical trial of Myopia, sponsored by CooperVision.
- Completed
- Registry status
- 35
- Enrollment target
- 1
- Study location
NCT05035017 is a study of Myopia that has completed, run by CooperVision. The registered enrollment target is 35 participants, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05035017, a study of Myopia, has completed, sponsored by CooperVision.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to confirm the design specifications of a Test lens and validate its clinical performance.
Conditions Studied
Interventions
- DEVICE Test Lens
- DEVICE Control Lens
Study Locations (1)
Indiana
- Indiana University School of Optometry - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2021-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05035017
The ClinicalTrials.gov registry entry for NCT05035017 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (87% lower). The listed sponsor is CooperVision, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Test Lens is the first listed.
NCT05035017 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT05035017 about?
NCT05035017 is a clinical study titled "Clinical Validation of the Apollo Daily Disposable Soft Contact Lenses". The purpose of this study was to confirm the design specifications of a Test lens and validate its clinical performance.
What is the current status of trial NCT05035017?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2021-06-17. Estimated completion is 2021-07-31.
What conditions does trial NCT05035017 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT05035017?
The interventions under investigation include: Test Lens (DEVICE), Control Lens (DEVICE).
Who is sponsoring clinical trial NCT05035017?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05035017 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Clinical Evaluation of WaveLight Plus LASIK
RECRUITING
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.